{
    "@graph": [
        {
            "@id": "gnd:4006780-4",
            "sameAs": "Bioreaktor"
        },
        {
            "@id": "gnd:4006890-0",
            "sameAs": "Biopharmazie"
        },
        {
            "@id": "gnd:4176074-8",
            "sameAs": "Prozessoptimierung"
        },
        {
            "@id": "https://www.tib.eu/de/suchen/id/TIBKAT%3A745999131",
            "@type": "bibo:Thesis",
            "P1053": "Online-Ressource (41 Bl. = 1,81 mb)",
            "contributor": [
                "B\u00fcchs, Jochen",
                "L\u00fcbbert, Andreas"
            ],
            "creator": "Sieblist, Christian Philipp",
            "identifier": [
                "(firstid)GBV:745999131",
                "(doi)10.25673/874",
                "(ppn)745999131"
            ],
            "publisher": "Universit\u00e4ts- und Landesbibliothek Sachsen-Anhalt",
            "http://purl.org/dc/elements/1.1/subject": [
                "(classificationName=linseach:mapping)cet",
                "(classificationName=bk, id=106405365)58.30 - Biotechnologie",
                "(classificationName=ddc-dbn)660",
                "(classificationName=ddc-dbn)620"
            ],
            "title": "Transport processes in currently used bioreactors : [kumulative Dissertation]",
            "abstract": [
                "Im Jahr 2010 wurden in Deutschland Biopharmazeutika im Wert von ca. 5,2 Milliarden Euro verkauft und derzeit befinden sich weltweit mindestens 460 neue biologische Wirkstoffe in der klinischen Entwicklung. Die jeweiligen Herstellprozesse sind technisch sehr aufwendig und gesetzlich mit hohen Anforderungen belegt. Zur Minimierung von Risiken und Aufwand ist die Herstellung daher meist auf wenige Produktionsstandorte und Anlagen begrenzt. Derzeit werden meist tierische Zelllinien zur Produktion rekombinanter therapeutischer Proteine eingesetzt, da diese die komplexen Glykosilierungen und posttranslationalen Modifikationen, welche zur therapeutische Wirksamkeit notwendig sind, korrekt durchf\u00fchren k\u00f6nnen. Die Kultivierung als auch das Scale Up der Produktionsprozesse vom Mikroliterma\u00dfstab bis hin zu R\u00fchrkesselbioreaktoren mit Arbeitsvolumen von 25m\u00b3 erfordert ein sehr hohes Prozessverst\u00e4ndnis um definierte und gleichm\u00e4\u00dfige Produktqualit\u00e4ten gew\u00e4hrleisten zu k\u00f6nnen. In dieser Dissertation werden einige fluiddynamische Problemstellungen und L\u00f6sungsm\u00f6glichkeiten f\u00fcr den Scale Up solcher industrieller Produktionsprozesse dargestellt.",
                "Biopharmaceuticals roughly worth 5.2 billion euros were sold in Germany in 2010 and over 460 new biological active substances are in clinical development worldwide currently. However the particular production processes are of a high technical complexity and have to comply with legal requirements. Therefore production processes are usually limited to few production sites and plants to minimize the risks and costs. For the production of recombinant therapeutic proteins are mostly animal cell lines used, because they are able to perform complex glycosylation and posttranslational modifications which are necessary for therapeutic efficacy. The cell cultivation and the scale-up of such an production process from microliter scale up to stirred vessels with a working volume of 25m\u00b3 require a high process knowledge in order to get equal and consistent product quality. In this thesis, some fluid-dynamic problems and possible solutions are presented to scale-up industrial production processes.",
                "Gro\u00dfe Zellkulturbioreaktoren; Str\u00f6mungsverhalten; Durchmischung; Stofftransport; Me\u00dftechniken; Pluronic\u00ae F68; Begaserfritten",
                "Large scale cell culture bioreactors; flow patterns; fluid mixing; mass transfer; measurement techniques; Pluronic\u00ae F68; fritted spargers"
            ],
            "dcterms:contributor": "Technische Informationsbibliothek (TIB)",
            "isPartOf": "(collectioncode)GBV-ODiss",
            "issued": "2012",
            "language": "http://id.loc.gov/vocabulary/iso639-1/de",
            "license": "commercial licence",
            "medium": "rda:termList/RDACarrierType/1018",
            "subject": [
                "gnd:4176074-8",
                "gnd:4006890-0",
                "gnd:4006780-4"
            ],
            "isLike": "doi:10.25673/874"
        }
    ],
    "@id": "urn:x-arq:DefaultGraphNode",
    "@context": {
        "sameAs": "http://www.w3.org/2002/07/owl#sameAs",
        "creator": "http://purl.org/dc/elements/1.1/creator",
        "abstract": "http://purl.org/dc/terms/abstract",
        "contributor": "http://purl.org/dc/elements/1.1/contributor",
        "identifier": "http://purl.org/dc/elements/1.1/identifier",
        "subject": {
            "@id": "http://purl.org/dc/terms/subject",
            "@type": "@id"
        },
        "publisher": "http://purl.org/dc/elements/1.1/publisher",
        "medium": {
            "@id": "http://purl.org/dc/terms/medium",
            "@type": "@id"
        },
        "license": "http://purl.org/dc/terms/license",
        "P1053": "http://iflastandards.info/ns/isbd/elements/P1053",
        "title": "http://purl.org/dc/elements/1.1/title",
        "issued": "http://purl.org/dc/terms/issued",
        "language": {
            "@id": "http://purl.org/dc/terms/language",
            "@type": "@id"
        },
        "isLike": {
            "@id": "http://umbel.org/umbel#isLike",
            "@type": "@id"
        },
        "isPartOf": "http://purl.org/dc/terms/isPartOf",
        "umbel": "http://umbel.org/umbel#",
        "rdau": "http://www.rdaregistry.info/Elements/u/#",
        "owl": "http://www.w3.org/2002/07/owl#",
        "dcterms": "http://purl.org/dc/terms/",
        "bibo": "http://purl.org/ontology/bibo/",
        "rdam": "http://www.rdaregistry.info/Elements/m/#",
        "gnd": "http://d-nb.info/gnd/",
        "isbd": "http://iflastandards.info/ns/isbd/elements/",
        "rda": "http://rdvocab.info/",
        "doi": "https://doi.org/"
    }
}